John M. Brooks, PhD

home / authors / john-m-brooks-phd

Articles

January 29th 2011

Effects of Health Savings Account Eligible Plans on Utilization and Expenditures

Mary E. Charlton, PhD Barcey T. Levy, PhD, MD Robin R. High, MBA, MA John E. Schneider, PhD John M. Brooks, PhD

The health savings account-eligible design may decrease costs and utilization, but it also may decrease use of preventive services.

September 15th 2008

Metastatic Non–Small Cell Lung Cancer: Costs Associated With Disease Progression

Kathleen M. Fox, MHS, PhD John M. Brooks, PhD Jennifer Kim, PharmD

The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Glaucoma | Image credit: Alessandro Grandini - stock.adobe.com

Published: November 21st 2024 | Updated: November 24th 2024

Polygenic Risk Scores Can Identify Patients Who Should Receive IOP-Lowering Treatment

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions